Gabriel Lindahl

1.1k total citations
22 papers, 425 citations indexed

About

Gabriel Lindahl is a scholar working on Oncology, Reproductive Medicine and Obstetrics and Gynecology. According to data from OpenAlex, Gabriel Lindahl has authored 22 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Reproductive Medicine and 7 papers in Obstetrics and Gynecology. Recurrent topics in Gabriel Lindahl's work include Ovarian cancer diagnosis and treatment (9 papers), PARP inhibition in cancer therapy (8 papers) and Endometrial and Cervical Cancer Treatments (7 papers). Gabriel Lindahl is often cited by papers focused on Ovarian cancer diagnosis and treatment (9 papers), PARP inhibition in cancer therapy (8 papers) and Endometrial and Cervical Cancer Treatments (7 papers). Gabriel Lindahl collaborates with scholars based in Sweden, Denmark and United States. Gabriel Lindahl's co-authors include Charlotta Dabrosin, Annelie Abrahamsson, Niina Saarinen, Mansoor Raza Mirza, Bente Lund, Line Bjørge, Anja Ør Knudsen, Susanne Malander, Johanna Mäenpää and Ulla Peen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Gabriel Lindahl

20 papers receiving 417 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gabriel Lindahl Sweden	9	304	207	107	68	52	22	425
J Belotte United States	10	83 0.3×	78 0.4×	107 1.0×	14 0.2×	44 0.8×	19	316
Lyndsay Willmott United States	10	129 0.4×	106 0.5×	136 1.3×	27 0.4×	42 0.8×	36	381
Salah T. Fayed Egypt	8	111 0.4×	84 0.4×	120 1.1×	11 0.2×	84 1.6×	16	337
Beidi Wang China	9	50 0.2×	104 0.5×	199 1.9×	7 0.1×	121 2.3×	14	400
Marjaneh Farazestanian Iran	7	92 0.3×	21 0.1×	243 2.3×	23 0.3×	35 0.7×	23	402
Genevieve Dall Australia	8	135 0.4×	19 0.1×	78 0.7×	77 1.1×	14 0.3×	10	270
Xiaohua Wu China	3	122 0.4×	53 0.3×	174 1.6×	6 0.1×	35 0.7×	3	407
Ailing Zhong China	13	124 0.4×	18 0.1×	192 1.8×	12 0.2×	23 0.4×	29	355
Laura M. Popoviciu United States	6	92 0.3×	20 0.1×	139 1.3×	26 0.4×	43 0.8×	6	333
Philip Hand United Kingdom	7	80 0.3×	66 0.3×	368 3.4×	66 1.0×	14 0.3×	7	460

Countries citing papers authored by Gabriel Lindahl

Since Specialization

Citations

This map shows the geographic impact of Gabriel Lindahl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriel Lindahl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriel Lindahl more than expected).

Fields of papers citing papers by Gabriel Lindahl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabriel Lindahl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriel Lindahl. The network helps show where Gabriel Lindahl may publish in the future.

Co-authorship network of co-authors of Gabriel Lindahl

This figure shows the co-authorship network connecting the top 25 collaborators of Gabriel Lindahl. A scholar is included among the top collaborators of Gabriel Lindahl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriel Lindahl. Gabriel Lindahl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sharma, Sudarshan, Gabriel Lindahl, Lisa M. Landrum, et al.. (2025). Patient-Reported Outcomes In Patients With Primary Advanced Or Recurrent Endometrial Cancer Treated With Chemotherapy Plus Dostarlimab Or Placebo In The ENGOT-EN6-NSGO/GOG3031/RUBY Trial Over 3 Years Of Follow-Up. International Journal of Gynecological Cancer. 35(2). 100243–100243.

Stålberg, Karin, et al.. (2025). Risk factors for lymph ascites after surgery for endometrial cancer and impact on lymphedema of the legs. A prospective longitudinal Swedish multicenter study. Acta Obstetricia Et Gynecologica Scandinavica. 104(5). 976–987. 1 indexed citations

Lindemann, Kristina, Dominique Berton-Rigaud, Jalid Sehouli, et al.. (2025). NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer. Gynecologic Oncology. 199. 79–87.

Lindahl, Gabriel, Zaheer Ali, Gabriela Vazquez Rodriguez, et al.. (2024). Zebrafish tumour xenograft models: a prognostic approach to epithelial ovarian cancer. npj Precision Oncology. 8(1). 53–53. 8 indexed citations

Mirza, Mansoor Raza, Jørn Herrstedt, Amit M. Oza, et al.. (2023). #161 Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase 3 trial of niraparib in patients with recurrent ovarian cancer. A15–A16. 8 indexed citations

Mirza, Mansoor Raza, Gabriel Lindahl, Sven Mahner, et al.. (2022). Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects. Cancer Research Communications. 2(11). 1436–1444. 5 indexed citations

Lindahl, Gabriel, et al.. (2022). Age as a potential predictor of acute side effects during chemoradiotherapy in primary cervical cancer patients. BMC Cancer. 22(1). 371–371. 6 indexed citations

O’Malley, David M., Athina Christopoulou, Myong Cheol Lim, et al.. (2022). O026/#560 Efficacy analysis by disease risk subgroup for the phase 3 athena-mono study (GOG-3020/engot-OV45) evaluating rucaparib maintenance treatment in patients with newly diagnosed ovarian cancer. International Journal of Gynecological Cancer. 32. A16–A16. 3 indexed citations

Stålberg, Karin, et al.. (2021). Impact of lymphadenectomy and lymphoedema on health‐related quality of life 1 year after surgery for endometrial cancer. A prospective longitudinal multicentre study. BJOG An International Journal of Obstetrics & Gynaecology. 129(3). 450–460. 4 indexed citations

10.

Stålberg, Karin, Janusz Marcickiewicz, Ulrika Ottander, et al.. (2021). Risk factors for lymphedema and method of assessment in endometrial cancer: a prospective longitudinal multicenter study. International Journal of Gynecological Cancer. 31(11). 1416–1427. 7 indexed citations

11.

Falandry, Claire, Saverio Cinieri, Florence Joly, et al.. (2021). 167 Safety and quality of life of first-line maintenance olaparib plus bevacizumab in older patients with advanced ovarian cancer in the PAOLA-1 trial. A201.3–A202. 3 indexed citations

12.

Stålberg, Karin, et al.. (2020). Incidence of lymphedema in the lower limbs and lymphocyst formation within one year of surgery for endometrial cancer: A prospective longitudinal multicenter study. Gynecologic Oncology. 159(1). 201–208. 18 indexed citations

13.

Mirza, Mansoor Raza, Bente Lund, René dePont Christensen, et al.. (2020). Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study.. Journal of Clinical Oncology. 38(15_suppl). 6012–6012. 13 indexed citations

14.

Mirza, Mansoor Raza, Elisabeth Åvall Lundqvist, Michael J. Birrer, et al.. (2019). Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. The Lancet Oncology. 20(10). 1409–1419. 187 indexed citations

15.

Lindahl, Gabriel, Annelie Abrahamsson, & Charlotta Dabrosin. (2019). Dietary flaxseed and tamoxifen affect the inflammatory microenvironment in vivo in normal human breast tissue of postmenopausal women. European Journal of Clinical Nutrition. 73(9). 1250–1259. 7 indexed citations

16.

Lindahl, Gabriel, et al.. (2019). Increased Extracellular Osteopontin Levels in Normal Human Breast Tissue at High Risk of Developing Cancer and Its Association With Inflammatory Biomarkers in situ. Frontiers in Oncology. 9. 746–746. 14 indexed citations

17.

Mirza, Mansoor Raza, Elisabeth Åvall‐Lundqvist, Michael J. Birrer, et al.. (2019). Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.. Journal of Clinical Oncology. 37(15_suppl). 5505–5505. 7 indexed citations

18.

Haldorsen, Ingfrid S., Elisabeth Åvall‐Lundqvist, Gabriel Lindahl, et al.. (2018). Cervical cancer staging, pretreatment planning, and surgical treatment in the Nordic countries—Survey from the Surgical Subcommittee of the Nordic Society of Gynecological Oncology. Acta Obstetricia Et Gynecologica Scandinavica. 97(10). 1178–1184. 3 indexed citations

19.

Bjurberg, Maria, et al.. (2015). [Cervical cancer is a clinical challenge].. PubMed. 112. 7 indexed citations

20.

Lindahl, Gabriel, Niina Saarinen, Annelie Abrahamsson, & Charlotta Dabrosin. (2010). Tamoxifen, Flaxseed, and the Lignan Enterolactone Increase Stroma- and Cancer Cell–Derived IL-1Ra and Decrease Tumor Angiogenesis in Estrogen-Dependent Breast Cancer. Cancer Research. 71(1). 51–60. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact